A. Mizuno, S. Lolachi and A. Pernet (2017). [Euglycemic ketoacidosis : a complication of SGLT2 inhibitors]. Revue medicale suisse, 13(565), 1164-1167.

PubMed 28639760

[Abstract]
Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a new category of oral antidiabetics recently indicated for the treatment of type 2 diabetes. Their mechanism of action (inhibition of renal reabsorption of glucose) and the fact that they do not induce hypoglycemia (as monotherapy) make their clinical use interesting. Various adverse events have however been reported regarding these drugs with the euglycemic ketoacidosis being the most serious. In this article we aim to review the possible mechanism of this side effect and recommendations for use of SGLT2 inhibitors by means of a case report.